Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 12/20 | 1.00 |
| ▸ | TTR | P02766 | 3/20 | 0.74 |
| ▸ | DPP4 | P27487 | 1/20 | 0.74 |
| ▸ | IAPP | P10997 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.64 |
| ▸ | GMNN | O75496 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | ESR1 | P03372 | 1/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.64 |
| ▸ | LCK | P06239 | 1/20 | 0.64 |
| ▸ | FYN | P06241 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butyl Caffeate SCHEMBL1879822 | 1.00 | APP (1.00) | APPTTRDPP4IAPPCYP3A4 | |
| SCHEMBL28418063 | 0.96 | APP (1.00) | APPTTRDPP4IAPPCYP3A4 | |
| SCHEMBL7953562 | 0.96 | APP (1.00) | APPTTRDPP4IAPPCYP3A4 | |
| SCHEMBL1427294 | 0.94 | APP (1.00) | APPTTRDPP4IAPPCYP3A4 | |
| SCHEMBL883450 | 0.94 | APP (1.00) | APPTTRDPP4IAPPCYP3A4 | |
| SCHEMBL19359050 | 0.94 | APP (1.00) | APPTTRDPP4IAPPCYP3A4 | |
| SCHEMBL19358979 | 0.94 | APP (1.00) | APPTTRDPP4IAPPCYP3A4 | |
| SCHEMBL19358968 | 0.94 | APP (1.00) | APPTTRDPP4IAPPCYP3A4 | |
| SCHEMBL16428904 | 0.94 | APP (1.00) | APPTTRDPP4IAPPCYP3A4 | |
| SCHEMBL1427296 | 0.94 | APP (1.00) | APPTTRDPP4IAPPCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113481658-A | Nano electrostatic spinning food preservative film mediated by butyl caffeate and endogenous NO type chitosan and preparation method and application thereof | 浙江工商大学 | 2021-10-08 | — | — | CN | claimed |
| CN-111296445-A | Laurella solanacearum targeted nano medicament and preparation method and application thereof | 江苏科技大学 | 2020-06-19 | — | — | CN | claimed |
| US-20150274633-A2 | PAIN RELIEF COMPOUNDS | UNIVERSITÉ CLERMONT AUVERGNE (FR) | 2015-10-01 | — | — | US | claimed |
| US-20150038466-A1 | PAIN RELIEF COMPOUNDS | ECOLE NATIONALE SUPERIEURE DE CHIMIE DE CLERMONT FERRAND (FR) | 2015-02-05 | — | — | US | claimed |
| EP-2061452-B1 | ANTI CANCER USE OF CAFFEIC ACID AND DERIVATIVES | PIRAMAL LIFE SCIENCES LTD (IN) | 2011-10-26 | — | — | EP | claimed |
| US-20100010002-A1 | ANTICANCER USE OF CAFFEIC ACID AND ITS DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-01-14 | — | — | US | claimed |
| EP-2061452-A2 | ANTI CANCER USE OF CAFFEIC ACID AND DERIVATIVES | Piramal Life Sciences Limited (IN) | 2009-05-27 | — | — | EP | claimed |
| WO-2008026125-A2 | ANTI CANCER USE OF CAFFEIC ACID AND DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-03-06 | — | — | WO | claimed |
| JP-60248645-A | — | — | None | — | — | JP | disclosed |
| CN-120114433-A | Application of natural benzoic acid compound in preparation of medicine for treating gastrointestinal diseases | 中国海洋大学 | 2025-06-10 | — | — | CN | disclosed |
| CN-117265775-A | Nanofiber preservative film, preparation method thereof and application thereof in antibacterial or ethylene degradation | 华南农业大学 | 2023-12-22 | — | — | CN | disclosed |
| CN-113384570-B | Application of caffeic acid methyl ester and triazole composition in preparation of antifungal products | 山东省妇幼保健院 | 2022-08-26 | — | — | CN | disclosed |
| CN-114894735-A | Method for rapidly screening silkworm feeding modifier for producing functional silk | 浙江理工大学 | 2022-08-12 | — | — | CN | disclosed |
| CN-111296445-B | Laurella solanacearum targeted nano medicament and preparation method and application thereof | 江苏科技大学 | 2022-03-11 | — | — | CN | disclosed |
| EP-0464859-A1 | A lipoxygenase inhibitor | GREEN CROSS CORPORATION (JP) | 1992-01-08 | — | — | EP | disclosed |
| EP-0464858-A1 | A lipoxygenase inhibitor | GREEN CROSS CORPORATION (JP) | 1992-01-08 | — | — | EP | disclosed |
| EP-0448091-A2 | Pharmaceutical composition containing slightly water-soluble drug | THE GREEN CROSS CORPORATION (JP) | 1991-09-25 | — | — | EP | disclosed |
| US-4733002-A | Lipoxygenase inhibitor | GREEN CROSS CORPORATION (JP) | 1988-03-22 | — | — | US | disclosed |
| JP-S60248645-A | CAFFEIC ACID DERIVATIVE | GREEN CROSS CORP:THE | 1985-12-09 | — | — | JP | disclosed |
| EP-0163270-A2 | A lipoxygenase inhibitor | GREEN CROSS CORPORATION (JP) | 1985-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010002-A1 | ANTICANCER USE OF CAFFEIC ACID AND ITS DERIVATIVES | ABL1, MCL1, SRC | APP 4524/4885TTR 2069/4885DPP4 2001/4885 |
| US-20150038466-A1 | PAIN RELIEF COMPOUNDS | OPRL1, OPRK1, TRPV1 | APP 3114/4885TTR 1663/4885DPP4 969/4885 |
| US-20150274633-A2 | PAIN RELIEF COMPOUNDS | OPRL1, OPRK1, TRPV1 | APP 3114/4885TTR 1663/4885DPP4 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.